Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Very high-protein and low-carbohydrate enteral nutrition formula and plasma glucose control in adults with type 2 diabetes mellitus: a randomized crossover trial.

Huhmann MB, Yamamoto S, Neutel JM, Cohen SS, Ochoa Gautier JB.

Nutr Diabetes. 2018 Aug 30;8(1):45. doi: 10.1038/s41387-018-0053-x.

2.

Human placental membrane as a wound cover for chronic diabetic foot ulcers: a prospective, postmarket, CLOSURE study.

Pacaccio DJ, Cazzell SM, Halperin GJ, Kasper MA, Neutel JM, O'Carroll BD, Reyzelman AM.

J Wound Care. 2018 Jul 1;27(Sup7):S28-S37. doi: 10.12968/jowc.2018.27.Sup7.S28.

PMID:
30008251
3.

Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide.

Neutel JM, Cushman WC, Lloyd E, Barger B, Handley A.

J Clin Hypertens (Greenwich). 2017 Sep;19(9):874-883. doi: 10.1111/jch.13009. Epub 2017 Jul 6.

4.

Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study.

Neutel JM, Giles TD, Punzi H, Weiss RJ, Li H, Finck A.

J Am Soc Hypertens. 2014 Dec;8(12):915-20. doi: 10.1016/j.jash.2014.09.017. Epub 2014 Sep 28.

PMID:
25492835
5.

Telmisartan in combination with hydrochlorothiazide 12.5 mg for the management of patients with hypertension.

Neldam S, Schumacher H, Kjeldsen SE, Neutel JM.

Curr Med Res Opin. 2014 Sep;30(9):1715-24. doi: 10.1185/03007995.2014.924912. Epub 2014 Jun 13.

PMID:
24834808
6.

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R; LAPLACE-2 Investigators.

JAMA. 2014 May 14;311(18):1870-82. doi: 10.1001/jama.2014.4030.

PMID:
24825642
7.

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.

Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott R, Wasserman SM, Bays H; MENDEL-2 Investigators.

J Am Coll Cardiol. 2014 Jun 17;63(23):2531-2540. doi: 10.1016/j.jacc.2014.03.018. Epub 2014 Mar 29.

8.

Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy.

Robinson JG, Rogers WJ, Nedergaard BS, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R.

Clin Cardiol. 2014 Apr;37(4):195-203. doi: 10.1002/clc.22252. Epub 2014 Jan 30.

9.

Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures.

Neutel JM, Zhao C, Karyekar CS.

Diabetes Ther. 2013 Dec;4(2):269-83. doi: 10.1007/s13300-013-0028-9. Epub 2013 Jul 24.

10.

Hypertension management: rationale for triple therapy based on mechanisms of action.

Neutel JM, Smith DH.

Cardiovasc Ther. 2013 Oct;31(5):251-8. doi: 10.1111/1755-5922.12015. Review.

PMID:
23121769
11.

Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups.

Chrysant SG, Germino FW, Neutel JM.

Am J Cardiovasc Drugs. 2012 Dec 1;12(6):375-89. doi: 10.2165/11636080-000000000-00000. Review.

PMID:
23116225
12.

Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy.

Hsueh WA, Shojaee A, Maa JF, Neutel JM.

Curr Med Res Opin. 2012 Nov;28(11):1809-18. doi: 10.1185/03007995.2012.740632. Epub 2012 Oct 30.

PMID:
23072496
13.

Efficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertension.

Germino FW, Neutel JM, Dubiel R, Maa JF, Chavanu KJ.

Am J Cardiovasc Drugs. 2012 Oct 1;12(5):325-33. doi: 10.2165/11635000-000000000-00000.

PMID:
22920048
14.

Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study.

Neutel JM, Mancia G, Black HR, Dahlöf B, Defeo H, Ley L, Vinisko R; TEAMSTA Severe HTN Study Investigators.

J Clin Hypertens (Greenwich). 2012 Apr;14(4):206-15. doi: 10.1111/j.1751-7176.2012.00595.x. Epub 2012 Feb 23.

15.

Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial.

Sharma AM, Bakris G, Neutel JM, Littlejohn TW, Kobe M, Ting N, Ley L.

Clin Ther. 2012 Mar;34(3):537-51. doi: 10.1016/j.clinthera.2012.02.004. Epub 2012 Mar 3.

PMID:
22386829
16.
18.

A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide.

Weir MR, Hsueh WA, Nesbitt SD, Littlejohn TJ 3rd, Graff A, Shojaee A, Waverczak WF, Qian C, Jones CJ, Neutel JM.

J Clin Hypertens (Greenwich). 2011 Jun;13(6):404-12. doi: 10.1111/j.1751-7176.2011.00437.x. Epub 2011 Feb 5.

19.

Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen.

Ram CV, Sachson R, Littlejohn T, Qian C, Shojaee A, Stoakes KA, Neutel JM.

Am J Cardiol. 2011 May 1;107(9):1346-52. doi: 10.1016/j.amjcard.2010.12.045.

PMID:
21497211
20.

Long-term blood pressure control: what can we do?

Neutel JM.

Postgrad Med. 2011 Jan;123(1):88-93. doi: 10.3810/pgm.2011.01.2249. Review.

PMID:
21293088
21.
22.

Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors.

Franklin SS, Neutel JM.

J Clin Hypertens (Greenwich). 2010 Jul 1;12(7):487-94. doi: 10.1111/j.1751-7176.2010.00294.x.

23.

Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice.

Neutel JM, Eaddy M, Lunacsek OE, Roberts C, Chen L, Kean AJ, Jackson JH.

J Clin Hypertens (Greenwich). 2010 Jun;12(6):396-406. doi: 10.1111/j.1751-7176.2010.00290.x.

24.

Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study.

Punzi H, Neutel JM, Kereiakes DJ, Shojaee A, Waverczak WF, Dubiel R, Maa JF.

Ther Adv Cardiovasc Dis. 2010 Aug;4(4):209-21. doi: 10.1177/1753944710374745. Epub 2010 Jun 2.

PMID:
20519261
25.

Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes.

Neutel JM, Kereiakes DJ, Waverczak WF, Stoakes KA, Xu J, Shojaee A.

Curr Med Res Opin. 2010 Mar;26(3):721-8. doi: 10.1185/03007990903553556.

PMID:
20085534
26.

Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy.

Neutel JM.

Curr Med Res Opin. 2010 Jan;26(1):213-22. doi: 10.1185/03007990903444434. Review.

PMID:
19921961
27.

Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.

Neutel JM, Franklin SS, Bhaumik A, Lapuerta P, Oparil S.

Clin Exp Hypertens. 2009 Oct;31(7):572-84. doi: 10.3109/10641960902929420.

PMID:
19886855
28.

Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I-II hypertension.

Neutel JM, Smith DH, Gradman AH.

J Hum Hypertens. 2010 Jan;24(1):64-73. doi: 10.1038/jhh.2009.33. Erratum in: J Hum Hypertens. 2010 Jun;24(6):430.

PMID:
19404314
29.

Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension.

Wolk R, Smith WB, Neutel JM, Rubino J, Xuan D, Mancuso J, Gilbert J, Pressler ML.

Hypertension. 2009 Jun;53(6):1091-7. doi: 10.1161/HYPERTENSIONAHA.109.132225. Epub 2009 Apr 27.

PMID:
19398651
30.

Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.

Chrysant SG, Neutel JM, Ferdinand KC; INCLUSIVE investigators.

J Natl Med Assoc. 2009 Apr;101(4):300-7.

PMID:
19397219
31.

Complementary mechanisms of angiotensin receptor blockers and calcium channel blockers in managing hypertension.

Neutel JM.

Postgrad Med. 2009 Mar;121(2):40-8. doi: 10.3810/pgm.2009.03.1975. Review.

PMID:
19332961
32.

Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.

Williams B, Lacourcière Y, Schumacher H, Gosse P, Neutel JM.

J Hum Hypertens. 2009 Sep;23(9):610-9. doi: 10.1038/jhh.2009.4. Epub 2009 Feb 19.

PMID:
19225530
33.

The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study.

Neutel JM, Bestermann WH, Dyess EM, Graff A, Kursun A, Sutradhar S, Yunis C.

J Clin Hypertens (Greenwich). 2009 Jan;11(1):22-30. doi: 10.1111/j.1751-7176.2008.00058.x.

34.

Magnitude of the early morning blood pressure surge in untreated hypertensive patients: a pooled analysis.

Neutel JM, Schumacher H, Gosse P, Lacourcière Y, Williams B.

Int J Clin Pract. 2008 Nov;62(11):1654-63. doi: 10.1111/j.1742-1241.2008.01892.x. Epub 2008 Sep 15.

PMID:
18795972
35.

Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial.

Ofili EO, Cable G, Neutel JM, Saunders E.

J Womens Health (Larchmt). 2008 Jul-Aug;17(6):931-8. doi: 10.1089/jwh.2008.0499.

36.

Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients.

Neutel JM.

Curr Med Res Opin. 2008 Aug;24(8):2389-401. doi: 10.1185/03007990802262457. Epub 2008 Jul 9. Review.

PMID:
18616863
37.

Initial combination therapy for rapid and effective control of moderate and severe hypertension.

Franklin SS, Neutel JM.

J Hum Hypertens. 2009 Jan;23(1):4-11. doi: 10.1038/jhh.2008.72. Epub 2008 Jul 10. Review.

PMID:
18615100
38.

Hypertension control in the elderly.

Neutel JM, Gilderman LI.

J Clin Hypertens (Greenwich). 2008 Jan;10(1 Suppl 1):33-9. Review.

39.

Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy.

Cushman WC, Neutel JM, Saunders E, Bakris GL, Ferdinand KC, Ofili EO, Sowers JR, Madder R, Weber MA.

Am J Geriatr Cardiol. 2008 Jan-Feb;17(1):27-36.

PMID:
18174757
40.

The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk.

Weir MR, Neutel JM, Bhaumik A, De Obaldia ME, Lapuerta P.

J Clin Hypertens (Greenwich). 2007 Dec;9(12 Suppl 5):23-30.

41.

Emerging insights in the first-step use of antihypertensive combination therapy.

Norris K, Neutel JM.

J Clin Hypertens (Greenwich). 2007 Dec;9(12 Suppl 5):5-14. Review.

42.

Hypertension control: still not there-how to select the right add-on therapy to reach goal blood pressures.

Neutel JM, Sica DA, Franklin SS.

J Clin Hypertens (Greenwich). 2007 Nov;9(11):889-96.

43.

Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate.

Kereiakes DJ, Neutel JM, Punzi HA, Xu J, Lipka LJ, Dubiel R.

Am J Cardiovasc Drugs. 2007;7(5):361-72.

PMID:
17953475
44.

A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.

Neutel JM, Franklin SS, Lapuerta P, Bhaumik A, Ptaszynska A.

J Hum Hypertens. 2008 Apr;22(4):266-74. Epub 2007 Oct 11.

PMID:
17928878
45.

The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials.

Gosse P, Neutel JM, Schumacher H, Lacourcière Y, Williams B, Davidai G.

Blood Press Monit. 2007 Jun;12(3):141-7.

PMID:
17496463
46.

Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker.

Izzo JL Jr, Neutel JM, Silfani T, Dubiel R, Walker F.

J Clin Hypertens (Greenwich). 2007 Jan;9(1):45-8.

47.

Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study.

Izzo JL Jr, Neutel JM, Silfani T, Dubiel R, Walker F.

J Clin Hypertens (Greenwich). 2007 Jan;9(1):36-44.

48.

Hypertension and its management: a problem in need of new treatment strategies.

Neutel JM.

J Renin Angiotensin Aldosterone Syst. 2000 Jun;1(2 Suppl):S10-3. Review.

PMID:
17199212
49.

Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension.

Neutel JM, Franklin SS, Oparil S, Bhaumik A, Ptaszynska A, Lapuerta P.

J Clin Hypertens (Greenwich). 2006 Dec;8(12):850-7; quiz 858-9.

50.

Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension.

White WB, Punzi HA, Murwin D, Koval SE, Davidai G, Neutel JM.

J Clin Hypertens (Greenwich). 2006 Sep;8(9):626-33.

Supplemental Content

Loading ...
Support Center